Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Korro Bio (KRRO) Other Accumulated Expenses (2019 - 2025)

Korro Bio (KRRO) has disclosed Other Accumulated Expenses for 4 consecutive years, with $111000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Other Accumulated Expenses fell 40.32% year-over-year to $111000.0, compared with a TTM value of $111000.0 through Sep 2025, down 40.32%, and an annual FY2024 reading of $277000.0, down 38.03% over the prior year.
  • Other Accumulated Expenses was $111000.0 for Q3 2025 at Korro Bio, down from $130000.0 in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $493000.0 in Q1 2025 and bottomed at $111000.0 in Q3 2025.
  • Average Other Accumulated Expenses over 4 years is $253400.0, with a median of $227000.0 recorded in 2022.
  • Peak annual rise in Other Accumulated Expenses hit 252.14% in 2025, while the deepest fall reached 47.37% in 2025.
  • Year by year, Other Accumulated Expenses stood at $207000.0 in 2022, then soared by 115.94% to $447000.0 in 2023, then plummeted by 38.03% to $277000.0 in 2024, then tumbled by 59.93% to $111000.0 in 2025.
  • Business Quant data shows Other Accumulated Expenses for KRRO at $111000.0 in Q3 2025, $130000.0 in Q2 2025, and $493000.0 in Q1 2025.